232 related articles for article (PubMed ID: 31262713)
21. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
22. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
23. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
24. p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
Cloer EW; Siesser PF; Cousins EM; Goldfarb D; Mowrey DD; Harrison JS; Weir SJ; Dokholyan NV; Major MB
Mol Cell Biol; 2018 Nov; 38(22):. PubMed ID: 30126895
[TBL] [Abstract][Full Text] [Related]
25. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
26. Chaperone-mediated autophagy degrades Keap1 and promotes Nrf2-mediated antioxidative response.
Zhu L; He S; Huang L; Ren D; Nie T; Tao K; Xia L; Lu F; Mao Z; Yang Q
Aging Cell; 2022 Jun; 21(6):e13616. PubMed ID: 35535673
[TBL] [Abstract][Full Text] [Related]
27. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of FAM129B protects cardiomyocytes from hypoxia/reoxygenation-induced injury by inhibiting apoptosis, oxidative stress, and inflammatory response via enhancing Nrf2/ARE activation.
Zeng G; Lian C; Li W; An H; Han Y; Fang D; Zheng Q
Environ Toxicol; 2022 May; 37(5):1018-1031. PubMed ID: 34995000
[TBL] [Abstract][Full Text] [Related]
29. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
[TBL] [Abstract][Full Text] [Related]
30. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.
Zeng H; Zhao X; Tang C
Cancer Chemother Pharmacol; 2021 Aug; 88(2):223-233. PubMed ID: 33907880
[TBL] [Abstract][Full Text] [Related]
32. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
33. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
[TBL] [Abstract][Full Text] [Related]
34. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
35. NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer.
Baird L; Yamamoto M
Mol Cell Biol; 2021 Jan; 41(2):. PubMed ID: 33139492
[TBL] [Abstract][Full Text] [Related]
36. WDR23 regulates NRF2 independently of KEAP1.
Lo JY; Spatola BN; Curran SP
PLoS Genet; 2017 Apr; 13(4):e1006762. PubMed ID: 28453520
[TBL] [Abstract][Full Text] [Related]
37. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-200a improves diabetic endothelial dysfunction by targeting KEAP1/NRF2.
Jiang Z; Wu J; Ma F; Jiang J; Xu L; Du L; Huang W; Wang Z; Jia Y; Lu L; Wu H
J Endocrinol; 2020 Apr; 245(1):129-140. PubMed ID: 32031966
[TBL] [Abstract][Full Text] [Related]
40. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]